| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.fredungroup.com | |
| Market Cap | 393.98 Cr. | |
| Enterprise Value(EV) | 462.46 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 29.13 | Trailing Twelve Months Ending 2023-09 |
| Price-Earning Ratio (PE) | 28.78 | Trailing Twelve Months Ending 2023-09 |
| Industry PE | 38.54 | Trailing Twelve Months Ending 2023-09 |
| Book Value / Share | 239.68 | Trailing Twelve Months Ending 2023-09 |
| Price to Book Value | 3.50 | Calculated using Price: 838.40 |
| Dividend Yield | 0.08 | Period Ending 2023-03 |
| No. of Shares Subscribed | 0.47 Cr. | 4,699,162 Shares |
| FaceValue | 10 | |
| About Fredun Pharmaceuticals Ltd. | ||
| The company is engaged in manufacturing of pharmaceutical products. | ||
| 1 Day |
|
-1.07% |
| 1 Week |
|
-4.82% |
| 1 Month |
|
-4.67% |
| 3 Month |
|
-6.86% |
| 6 Month |
|
+1.00% |
| 1 Year |
|
-38.58% |
| 2 Year |
|
+69.68% |
| 5 Year |
|
+160.74% |
| 10 Year |
|
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 9.68 | 33.46 | 33.88 | 13.02 | 14.59 | 4.74 | 4.77 | 11.42 | 13.86 | |
| Return on Capital Employed (%) | 14.23 | 24.67 | 18.16 | 15.90 | 20.56 | 10.36 | 9.53 | 13.15 | 18.35 | |
| Return on Assets (%) | 1.26 | 3.23 | 2.88 | 2.59 | 4.84 | 1.54 | 1.33 | 3.63 | 4.86 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 3 | 4 | 7 | 22 | 39 | 41 | 43 | 68 | 96 | 111 | |
| Non Curr. Liab. | 4 | 7 | 8 | 4 | 13 | 14 | 32 | 45 | 55 | 20 | |
| Curr. Liab. | 16 | 32 | 40 | 53 | 53 | 86 | 86 | 74 | 106 | 147 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 279 | |
| Non Curr. Assets | 10 | 15 | 21 | 28 | 32 | 32 | 32 | 34 | 41 | 45 | |
| Curr. Assets | 13 | 28 | 35 | 51 | 73 | 109 | 130 | 153 | 216 | 234 | |
| Misc. Exp. not W/O | 0 | ||||||||||
| Total Assets | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 279 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09 Rs. Cr. TTM |
| Net Sales | 25 | 42 | 57 | 60 | 97 | 113 | 134 | 224 | 275 | 302 | |
| Other Income | 0 | 1 | 2 | 0 | 1 | 1 | 1 | 2 | 2 | ||
| Total Income | 26 | 43 | 59 | 60 | 98 | 113 | 135 | 226 | 277 | 302 | |
| Total Expenditure | -24 | -38 | -53 | -54 | -87 | -104 | -125 | -211 | -246 | -265 | |
| PBIDT | 2 | 5 | 5 | 6 | 11 | 9 | 11 | 16 | 31 | 37 | |
| Interest | -1 | -2 | -2 | -2 | -3 | -4 | -4 | -5 | -10 | -11 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -2 | -2 | -2 | -3 | -3 | |
| Taxation | 0 | -1 | -1 | -1 | -2 | -1 | -1 | -2 | -7 | -9 | |
| Exceptional Items | 0 | 0 | -1 | ||||||||
| PAT | 0 | 1 | 1 | 2 | 4 | 2 | 2 | 6 | 11 | 14 | |
| Adjusted EPS | 1 | 4 | 5 | 4 | 11 | 5 | 5 | 14 | 24 | 30 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | -1 | 2 | 3 | 4 | 17 | 1 | -11 | 0 | -2 | -14 | |
| Cash Fr. Inv. | -2 | -3 | -6 | -7 | -8 | -5 | -1 | -1 | -4 | -9 | |
| Cash Fr. Finan. | 2 | 1 | 3 | 3 | -8 | 4 | 14 | -1 | 7 | 25 | |
| Net Change | 0 | 0 | 1 | -1 | 1 | 0 | 2 | -2 | 1 | 1 | |
| Cash & Cash Eqvt | 0 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 3 |
|
Fri, 08 Dec 2023
Board Meeting Intimation for Prior Intimation For Fund Raising Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/12/2023 inter alia to consider and approve for fund raising upto Rs. 120 crores by way of further public offer right issue ADR/GDR/FCCB QIP Debt issue preferential issue or any other method. |
|
Thu, 07 Dec 2023
Closure of Trading Window Pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 and Code of Conduct for Prevention of Insider Trading of Fredun Pharmaceuticals Ltd the trading window for dealing in securities of the Company will remain closed for designated persons and their immediative relatives with effect from December 07 2023 till 48 hours after the end of the Board Meeting wherein the approval for raising funds would be considered approved and declared. The said information is being notified to all designated persons under the above regulations. |
|
Tue, 05 Dec 2023
Board Meeting Outcome for ALLOTMENT OF 5000 EQUITY SHARES TO NON-PROMOTER UPON CONVERSION OF WARRANTS INTO EQUITY SHARES This is to inform you that the Board of the Directors of the Company had pursuant to the approval of Shareholders in their Extra-Ordinary General Meeting held on September 23 2022 has done allotment of convertible warrants on preferential basis to Promoters and Non-promoters on October 15 2022.Further we would like to inform that the Warrant Holder have paid the balance of the consideration aggregating to Rs. 24 90 500/- and have applied for exercising their rights for conversion of 5 000 warrants into equivalent number of Equity Shares. |
| Fri, 08 Dec 2023 |
Higher Delivery Quantity
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
Opening at High
|
Closing Below Previous Low
|
Equities
M.F.
Sectors
StockEdge Social